Finding specific imaging and fluid biomarkers for future ARSACS treatment trials:

join an international biomarker-MRI study on ARSACS

Study # 2 - More advanced MRI Study in Quebec and Germany

To prepare future treatment trials in ARSACS, robust information is necessary on the natural disease course of the disease. This is the prerequisite to plan future treatment trials and to perform sample size calculations for these treatment trials. In addition, biomarkers identified in blood and by brain imaging will strongly help to initiate treatment trials for ARSACS.

A transatlantic network of ARSACS centers in Quebec and Germany has launched a multi-center study which is dedicated to collect these urgently required natural history data and biomaterials for biomarkers. We would welcome all persons affected by ARSACS to join this study and thus to support the preparation of future treatment trials.

All you need is an outpatient visit (including an MRI and blood sampling) at one of the following centers in Quebec or Germany:

(1) Center of Neurology & Hertie-Institute for Clinical Neurology, University of Tübingen, Germany; contact partner: Prof. Matthias Synofzik, matthias.synofzik@uni-tuebingen.de

(2) Montreal Neurological Institute, McGill University, Montreal, QC, Canada; contact partner: Dr. Roberta La Piana, roberta.lapiana@mail.mcgill.ca; 514-398-3334

(3) Centre intégré universitaire de la Capitale-Nationale, Quebec, QC, Canada; contact partner: Dr. Xavier Rodrigue, xav_rod@hotmail.com.

(4) CIUSSS Saguenay-Lac-St-Jean, University of Sherbrooke, Jonquières, QC, Canada; contact partner: Dr. Cynthia Gagnon, cynthia.gagnon4@usherbrooke.ca; 418-695-7700 extension 2756

Only visits at one of these centers participating in this study, but not in other centers, will make a contribution to the study.

For further questions, please contact Dr. Friedemann Bender, Center of Neurology and Hertie-Institute for Clinical Brain Research, Tübingen Germany, friedemann.bender@med.uni-tuebingen.de.

December, 2018